LibraryBy pinki shah / May 14, 2022 Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title of Presentation Type of Media — Video Document Audio Event 2024 Event — 2025 MaTOS Breast 2025 MaTOS GU 2025 PRIMO 2025 South Florida GI Cancer Symposium 2025 Winter Cancer Symposium (WCS) 2024 Advances in Oncology Conference 2024 Best of WCLC San Francisco 2024 California Cancer Consortium Conference (CCC) 2024 MaTOS Lungs 2024 MLS Cleveland 2024 MLS Irvine 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PACC Miami 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 Updates in Cancer Therapies 2024 WCS Clear Displaying 1,801 - 1,825 of 2,995 « 1 … 71 72 73 74 75 … 120 » Other Immunotherapy Targets & Agents- Advanced NSCLC By: Joel Neal, MD, PhD View PDF Other Immunotherapy Targets & Agents- Advanced NSCLC By: Joel Neal, MD, PhD View Video Other Immunotherapy Targets & Agents- Advanced NSCLC By: Joel Neal, MD, PhD View PDF Other Immunotherapy Targets & Agents- Advanced NSCLC By: Joel Neal, MD, PhD View Video Other Immunotherapy Targets & Agents- Advanced NSCLC By: Joel Neal, MD, PhD View PDF Other Immunotherapy Targets & Agents- Advanced NSCLC By: Joel Neal, MD, PhD View Video Session III - Systemic Treatment for Advanced Stage Non-Small Cell Lung Cancer By: Joel Neal, MD, PhD, David Gandara, MD, Collin Blakely, MD, PhD, Karen Kelly, MD, Jonathan W. Riess, MD, MS View Video Surgery for Early-Stage NSCLC By: Johannes Kratz, MD, PhD View PDF Surgery for Early-Stage NSCLC By: Johannes Kratz, MD, PhD View PDF Surgery for Early-Stage NSCLC By: Johannes Kratz, MD, PhD View Video Stage III NSCLC– Surgical/ Combined Modality By: Johannes R. Kratz, MD View PDF Stage III NSCLC– Surgical/ Combined Modality By: Johannes R. Kratz, MD View Video Surgery for Early-Stage NSCLC By: Johannes R. Kratz, MD View PDF Stage III NSCLC – Surgical/Combined Modality By: Johannes R. Kratz, MD View PDF Surgery for Early-Stage NSCLC By: Johannes R. Kratz, MD View Video Stage III NSCLC – Surgical/Combined Modality By: Johannes R. Kratz, MD View Video Exon 20 and Uncommon EGFR Sensitive Mutations By: John Heymach, MD View PDF RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up? By: John Heymach, MD View PDF Exon 20 and Uncommon EGFR Sensitive Mutations By: John Heymach, MD View Video RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up? By: John Heymach, MD View Video Novel Mechanisms of Resistance Identified for Diverse TKIs in NSCLC By: John Heymach, MD, PhD View PDF Novel Mechanisms of Resistance Identified for Diverse TKIs in NSCLC By: John Heymach, MD, PhD View Video Updates in Targeted Therapy for NSCLC By: Jonathan Riess - MD - MS View Video New Therapeutic Directions in Lung Cancer By: Jonathan Riess, MD View PDF Management of EGFR-mutant NSCLC By: Jonathan Riess, MD, MS View PDF
